{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:06:26Z","timestamp":1793862386022,"version":"4.6.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T00:00:00Z","timestamp":1509408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemotherapy promotes the development of cachexia, a debilitating condition characterized by muscle and fat loss. ACVR2B\/Fc, an inhibitor of the Activin Receptor 2B signaling, has been shown to preserve muscle mass and prolong survival in tumor hosts, and to increase bone mass in models of osteogenesis imperfecta and muscular dystrophy. We compared the effects of ACVR2B\/Fc on muscle and bone mass in mice exposed to Folfiri. In addition to impairing muscle mass and function, Folfiri had severe negative effects on bone, as shown by reduced trabecular bone volume fraction (BV\/TV), thickness (Tb.Th), number (Tb.N), connectivity density (Conn.Dn), and by increased separation (Tb.Sp) in trabecular bone of the femur and vertebra. ACVR2B\/Fc prevented the loss of muscle mass and strength, and the loss of trabecular bone in femurs and vertebrae following Folfiri administration. Neither Folfiri nor ACVR2B\/Fc had effects on femoral cortical bone, as shown by unchanged cortical bone volume fraction (Ct.BV\/TV), thickness (Ct.Th) and porosity. Our results suggest that Folfiri is responsible for concomitant muscle and bone degeneration, and that ACVR2B\/Fc prevents these derangements. Future studies are required to determine if the same protective effects are observed in combination with other anticancer regimens or in the presence of cancer.<\/jats:p>","DOI":"10.1038\/s41598-017-15040-1","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T12:05:12Z","timestamp":1508933112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["ACVR2B\/Fc counteracts chemotherapy-induced loss of muscle and bone mass"],"prefix":"10.1038","volume":"7","author":[{"given":"Rafael","family":"Barreto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kitase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra C.","family":"Colston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion E.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda F.","family":"Bonewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"15040_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA: a cancer journal for clinicians \n                           67, 7\u201330, https:\/\/doi.org\/10.3322\/caac.21387 (2017).","journal-title":"CA: a cancer journal for clinicians"},{"key":"15040_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. The lancet oncology \n                           12, 489\u2013495, https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7 (2011).","journal-title":"The lancet oncology"},{"key":"15040_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/01.mco.0000078984.18774.02","volume":"6","author":"P Costelli","year":"2003","unstructured":"Costelli, P. & Baccino, F. M. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Current opinion in clinical nutrition and metabolic care \n                           6, 407\u2013412, https:\/\/doi.org\/10.1097\/01.mco.0000078984.18774.02 (2003).","journal-title":"Current opinion in clinical nutrition and metabolic care"},{"key":"15040_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale, M. J. Mechanisms of cancer cachexia. Physiological reviews \n                           89, 381\u2013410, https:\/\/doi.org\/10.1152\/physrev.00016.2008 (2009).","journal-title":"Physiological reviews"},{"key":"15040_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell metabolism \n                           16, 153\u2013166, https:\/\/doi.org\/10.1016\/j.cmet.2012.06.011 (2012).","journal-title":"Cell metabolism"},{"key":"15040_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13539-010-0002-6","volume":"1","author":"SV Haehling","year":"2010","unstructured":"Haehling, S. V. & Anker, S. D. Cachexia as a major underestimated and unmet medical need: facts and numbers. Journal of Cachexia, Sarcopenia and Muscle \n                           1, 1\u20135 (2010).","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"key":"15040_CR7","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research: an official journal of the American Association for Cancer Research \n                           12, 6243s\u20136249s, https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0931 (2006).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"15040_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","volume":"64","author":"CE DeSantis","year":"2014","unstructured":"DeSantis, C. E. et al. Cancer treatment and survivorship statistics, 2014. CA: a cancer journal for clinicians \n                           64, 252\u2013271, https:\/\/doi.org\/10.3322\/caac.21235 (2014).","journal-title":"CA: a cancer journal for clinicians"},{"key":"15040_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fphys.2016.00679","volume":"7","author":"A Bonetto","year":"2017","unstructured":"Bonetto, A. et al. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Front Physiol \n                           7, 679, https:\/\/doi.org\/10.3389\/fphys.2016.00679 (2017).","journal-title":"Front Physiol"},{"key":"15040_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13539-012-0062-x","volume":"3","author":"FE Pedroso","year":"2012","unstructured":"Pedroso, F. E. et al. Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. Journal of cachexia, sarcopenia and muscle \n                           3, 199\u2013211, https:\/\/doi.org\/10.1007\/s13539-012-0062-x (2012).","journal-title":"Journal of cachexia, sarcopenia and muscle"},{"key":"15040_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","volume":"2","author":"R Silbermann","year":"2013","unstructured":"Silbermann, R. & Roodman, G. D. Myeloma bone disease: Pathophysiology and management. J Bone Oncol \n                           2, 59\u201369, https:\/\/doi.org\/10.1016\/j.jbo.2013.04.001 (2013).","journal-title":"J Bone Oncol"},{"key":"15040_CR12","doi-asserted-by":"publisher","first-page":"e00144","DOI":"10.1002\/phy2.144","volume":"1","author":"E Choi","year":"2013","unstructured":"Choi, E. et al. Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep \n                           1, e00144, https:\/\/doi.org\/10.1002\/phy2.144 (2013).","journal-title":"Physiol Rep"},{"key":"15040_CR13","doi-asserted-by":"publisher","first-page":"e0132786","DOI":"10.1371\/journal.pone.0132786","volume":"10","author":"SH Greco","year":"2015","unstructured":"Greco, S. H. et al. TGF-beta Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia. PloS one \n                           10, e0132786, https:\/\/doi.org\/10.1371\/journal.pone.0132786 (2015).","journal-title":"PloS one"},{"key":"15040_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","volume":"5","author":"GA Curt","year":"2000","unstructured":"Curt, G. A. et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The oncologist \n                           5, 353\u2013360 (2000).","journal-title":"The oncologist"},{"key":"15040_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF00364968","volume":"1","author":"A Glaus","year":"1993","unstructured":"Glaus, A. Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer \n                           1, 305\u2013315 (1993).","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"15040_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","volume":"11","author":"TA Guise","year":"2006","unstructured":"Guise, T. A. Bone loss and fracture risk associated with cancer therapy. The oncologist \n                           11, 1121\u20131131, https:\/\/doi.org\/10.1634\/theoncologist.11-10-1121 (2006).","journal-title":"The oncologist"},{"key":"15040_CR17","doi-asserted-by":"publisher","first-page":"43442","DOI":"10.18632\/oncotarget.9779","volume":"7","author":"R Barreto","year":"2016","unstructured":"Barreto, R. et al. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs. Oncotarget \n                           7, 43442\u201343460, https:\/\/doi.org\/10.18632\/oncotarget.9779 (2016).","journal-title":"Oncotarget"},{"key":"15040_CR18","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/jcp.23034","volume":"227","author":"T Shandala","year":"2012","unstructured":"Shandala, T. et al. The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss. Journal of cellular physiology \n                           227, 2889\u20132897, https:\/\/doi.org\/10.1002\/jcp.23034 (2012).","journal-title":"Journal of cellular physiology"},{"key":"15040_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00330-005-0010-7","volume":"16","author":"HJ Williams","year":"2006","unstructured":"Williams, H. J. & Davies, A. M. The effect of X-rays on bone: a pictorial review. Eur Radiol \n                           16, 619\u2013633, https:\/\/doi.org\/10.1007\/s00330-005-0010-7 (2006).","journal-title":"Eur Radiol"},{"key":"15040_CR20","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines, J., Oleske, D. M. & Cobleigh, M. A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology \n                           14, 1718\u20131729, https:\/\/doi.org\/10.1200\/JCO.1996.14.5.1718 (1996).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"15040_CR21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","volume":"38","author":"P Hadji","year":"2012","unstructured":"Hadji, P. et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev \n                           38, 798\u2013806, https:\/\/doi.org\/10.1016\/j.ctrv.2012.02.008 (2012).","journal-title":"Cancer Treat Rev"},{"key":"15040_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10549-010-0899-7","volume":"123","author":"DA Cameron","year":"2010","unstructured":"Cameron, D. A., Douglas, S., Brown, J. E. & Anderson, R. A. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat \n                           123, 805\u2013814, https:\/\/doi.org\/10.1007\/s10549-010-0899-7 (2010).","journal-title":"Breast Cancer Res Treat"},{"key":"15040_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.taap.2011.04.019","volume":"254","author":"M Nurmio","year":"2011","unstructured":"Nurmio, M. et al. Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. Toxicol Appl Pharmacol \n                           254, 267\u2013279, https:\/\/doi.org\/10.1016\/j.taap.2011.04.019 (2011).","journal-title":"Toxicol Appl Pharmacol"},{"key":"15040_CR24","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine \n                           351, 1502\u20131512, https:\/\/doi.org\/10.1056\/NEJMoa040720 (2004).","journal-title":"The New England journal of medicine"},{"key":"15040_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet \n                           376, 1147\u20131154, https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X (2010).","journal-title":"Lancet"},{"key":"15040_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clnu.2009.12.004","volume":"29","author":"M Muscaritoli","year":"2010","unstructured":"Muscaritoli, M. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) \u201ccachexia-anorexia in chronic wasting diseases\u201d and \u201cnutrition in geriatrics\u201d. Clinical nutrition \n                           29, 154\u2013159, https:\/\/doi.org\/10.1016\/j.clnu.2009.12.004 (2010).","journal-title":"Clinical nutrition"},{"key":"15040_CR27","doi-asserted-by":"crossref","unstructured":"Biskup, E., Cai, F. & Vetter, M. Bone targeted therapies in advanced breast cancer. Swiss Med Wkly \n                           100, w14440, doi:smw.2017.14440 (2017).","DOI":"10.4414\/smw.2017.14440"},{"key":"15040_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","volume":"23","author":"S Kir","year":"2016","unstructured":"Kir, S. et al. PTH\/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer. Cell metabolism \n                           23, 315\u2013323, https:\/\/doi.org\/10.1016\/j.cmet.2015.11.003 (2016).","journal-title":"Cell metabolism"},{"key":"15040_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature \n                           513, 100\u2013104, https:\/\/doi.org\/10.1038\/nature13528 (2014).","journal-title":"Nature"},{"key":"15040_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/MCO.0000000000000357","volume":"20","author":"SS Thomas","year":"2017","unstructured":"Thomas, S. S. & Mitch, W. E. Parathyroid hormone stimulates adipose tissue browning: a pathway to muscle wasting. Current opinion in clinical nutrition and metabolic care \n                           20, 153\u2013157, https:\/\/doi.org\/10.1097\/MCO.0000000000000357 (2017).","journal-title":"Current opinion in clinical nutrition and metabolic care"},{"key":"15040_CR31","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","volume":"391","author":"ME Benny Klimek","year":"2010","unstructured":"Benny Klimek, M. E. et al. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochemical and biophysical research communications \n                           391, 1548\u20131554, https:\/\/doi.org\/10.1016\/j.bbrc.2009.12.123 (2010).","journal-title":"Biochemical and biophysical research communications"},{"key":"15040_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell \n                           142, 531\u2013543, https:\/\/doi.org\/10.1016\/j.cell.2010.07.011 (2010).","journal-title":"Cell"},{"key":"15040_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/mus.21743","volume":"42","author":"KJ Morine","year":"2010","unstructured":"Morine, K. J. et al. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve \n                           42, 722\u2013730, https:\/\/doi.org\/10.1002\/mus.21743 (2010).","journal-title":"Muscle Nerve"},{"key":"15040_CR34","doi-asserted-by":"publisher","first-page":"18117","DOI":"10.1073\/pnas.0505996102","volume":"102","author":"SJ Lee","year":"2005","unstructured":"Lee, S. J. et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences of the United States of America \n                           102, 18117\u201318122, https:\/\/doi.org\/10.1073\/pnas.0505996102 (2005).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"15040_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep32695","volume":"6","author":"TA Nissinen","year":"2016","unstructured":"Nissinen, T. A. et al. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci Rep \n                           6, 32695, https:\/\/doi.org\/10.1038\/srep32695 (2016).","journal-title":"Sci Rep"},{"key":"15040_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-016-0098-2","volume":"6","author":"S Hatakeyama","year":"2016","unstructured":"Hatakeyama, S. et al. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet Muscle \n                           6, 26, https:\/\/doi.org\/10.1186\/s13395-016-0098-2 (2016).","journal-title":"Skelet Muscle"},{"key":"15040_CR37","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.1038\/boneres.2014.42","volume":"3","author":"DJ DiGirolamo","year":"2015","unstructured":"DiGirolamo, D. J., Singhal, V., Chang, X., Lee, S. J. & Germain-Lee, E. L. Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta. Bone Res \n                           3, 14042, https:\/\/doi.org\/10.1038\/boneres.2014.42 (2015).","journal-title":"Bone Res"},{"key":"15040_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1366-3","volume":"18","author":"T Puolakkainen","year":"2017","unstructured":"Puolakkainen, T. et al. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy. BMC Musculoskelet Disord \n                           18, 20, https:\/\/doi.org\/10.1186\/s12891-016-1366-3 (2017).","journal-title":"BMC Musculoskelet Disord"},{"key":"15040_CR39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fphys.2016.00472","volume":"7","author":"R Barreto","year":"2016","unstructured":"Barreto, R. et al. Cancer and chemotherapy contribute to muscle loss by activating common signaling pathways. Frontiers in Physiology \n                           7, 472, https:\/\/doi.org\/10.3389\/fphys.2016.00472 (2016).","journal-title":"Frontiers in Physiology"},{"key":"15040_CR40","first-page":"369","volume":"12","author":"D Cella","year":"1998","unstructured":"Cella, D., Peterman, A., Passik, S., Jacobsen, P. & Breitbart, W. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) \n                           12, 369\u2013377 (1998).","journal-title":"Oncology (Williston Park)"},{"key":"15040_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0885-3924(99)00082-2","volume":"18","author":"PB Jacobsen","year":"1999","unstructured":"Jacobsen, P. B. et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage \n                           18, 233\u2013242 (1999).","journal-title":"J Pain Symptom Manage"},{"key":"15040_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1188\/ONF.537-546","volume":"29","author":"LM Nail","year":"2002","unstructured":"Nail, L. M. Fatigue in patients with cancer. Oncol Nurs Forum \n                           29, 537, https:\/\/doi.org\/10.1188\/02.ONF.537-546 (2002).","journal-title":"Oncol Nurs Forum"},{"key":"15040_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1046\/j.1523-5394.2001.009003119.x","volume":"9","author":"V Mock","year":"2001","unstructured":"Mock, V. et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract \n                           9, 119\u2013127 (2001).","journal-title":"Cancer Pract"},{"key":"15040_CR44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-7-102","volume":"7","author":"A Montazeri","year":"2009","unstructured":"Montazeri, A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes \n                           7, 102, https:\/\/doi.org\/10.1186\/1477-7525-7-102 (2009).","journal-title":"Health Qual Life Outcomes"},{"key":"15040_CR45","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ctrv.2015.09.003","volume":"41","author":"S D\u2019Oronzo","year":"2015","unstructured":"D\u2019Oronzo, S., Stucci, S., Tucci, M. & Silvestris, F. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev \n                           41, 798\u2013808, https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.003 (2015).","journal-title":"Cancer Treat Rev"},{"key":"15040_CR46","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1463-1318.2010.02206.x","volume":"13","author":"F Montagnani","year":"2011","unstructured":"Montagnani, F., Chiriatti, A., Turrisi, G., Francini, G. & Fiorentini, G. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland \n                           13, 846\u2013852, https:\/\/doi.org\/10.1111\/j.1463-1318.2010.02206.x (2011).","journal-title":"Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland"},{"key":"15040_CR47","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0140-6736(03)14186-4","volume":"362","author":"K Ahlberg","year":"2003","unstructured":"Ahlberg, K., Ekman, T., Gaston-Johansson, F. & Mock, V. Assessment and management of cancer-related fatigue in adults. Lancet \n                           362, 640\u2013650, https:\/\/doi.org\/10.1016\/S0140-6736(03)14186-4 (2003).","journal-title":"Lancet"},{"key":"15040_CR48","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/cncr.11742","volume":"98","author":"R Stasi","year":"2003","unstructured":"Stasi, R., Abriani, L., Beccaglia, P., Terzoli, E. & Amadori, S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer \n                           98, 1786\u20131801, https:\/\/doi.org\/10.1002\/cncr.11742 (2003).","journal-title":"Cancer"},{"key":"15040_CR49","doi-asserted-by":"publisher","unstructured":"Patrick, D. L. et al. National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr, 9\u201316, doi:https:\/\/doi.org\/10.1093\/jncimonographs\/djg014 (2004).","DOI":"10.1093\/jncimonographs\/djg014"},{"key":"15040_CR50","doi-asserted-by":"publisher","unstructured":"NHLBI Workshop summary. Respiratory muscle fatigue. Report of the Respiratory Muscle Fatigue Workshop Group. Am Rev Respir Dis \n                           142, 474\u2013480, doi:https:\/\/doi.org\/10.1164\/ajrccm\/142.2.474 (1990).","DOI":"10.1164\/ajrccm\/142.2.474"},{"key":"15040_CR51","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans, W. J. et al. Cachexia: a new definition. Clinical nutrition \n                           27, 793\u2013799, https:\/\/doi.org\/10.1016\/j.clnu.2008.06.013 (2008).","journal-title":"Clinical nutrition"},{"key":"15040_CR52","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/cncr.22993","volume":"110","author":"PB Jacobsen","year":"2007","unstructured":"Jacobsen, P. B. et al. Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer \n                           110, 1851\u20131859, https:\/\/doi.org\/10.1002\/cncr.22993 (2007).","journal-title":"Cancer"},{"key":"15040_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpainsymman.2009.06.011","volume":"39","author":"G Prue","year":"2010","unstructured":"Prue, G., Allen, J., Gracey, J., Rankin, J. & Cramp, F. Fatigue in gynecological cancer patients during and after anticancer treatment. J Pain Symptom Manage \n                           39, 197\u2013210, https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.06.011 (2010).","journal-title":"J Pain Symptom Manage"},{"key":"15040_CR54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/00000421-199808000-00007","volume":"21","author":"MA Rosenthal","year":"1998","unstructured":"Rosenthal, M. A. & Oratz, R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol \n                           21, 352\u2013354 (1998).","journal-title":"Am J Clin Oncol"},{"key":"15040_CR55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3912\/OJIN.Vol8No01HirshPsy02","volume":"8","author":"C Visovsky","year":"2003","unstructured":"Visovsky, C. & Schneider, S. M. Cancer-related fatigue. Online J Issues Nurs \n                           8, 8 (2003).","journal-title":"Online J Issues Nurs"},{"key":"15040_CR56","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.20777","volume":"103","author":"DJ Brown","year":"2005","unstructured":"Brown, D. J., McMillan, D. C. & Milroy, R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer \n                           103, 377\u2013382, https:\/\/doi.org\/10.1002\/cncr.20777 (2005).","journal-title":"Cancer"},{"key":"15040_CR57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/pcan.2008.51","volume":"12","author":"DA Galvao","year":"2009","unstructured":"Galvao, D. A. et al. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis \n                           12, 198\u2013203, https:\/\/doi.org\/10.1038\/pcan.2008.51 (2009).","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"15040_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-005-5991-z","volume":"94","author":"S Hayes","year":"2005","unstructured":"Hayes, S., Battistutta, D. & Newman, B. Objective and subjective upper body function six months following diagnosis of breast cancer. Breast Cancer Res Treat \n                           94, 1\u201310, https:\/\/doi.org\/10.1007\/s10549-005-5991-z (2005).","journal-title":"Breast Cancer Res Treat"},{"key":"15040_CR59","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1200\/JCO.2001.19.13.3226","volume":"19","author":"H Knobel","year":"2001","unstructured":"Knobel, H. et al. Late medical complications and fatigue in Hodgkin\u2019s disease survivors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology \n                           19, 3226\u20133233 (2001).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"15040_CR60","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1188\/09.ONF.194-202","volume":"36","author":"M Luctkar-Flude","year":"2009","unstructured":"Luctkar-Flude, M., Groll, D., Woodend, K. & Tranmer, J. Fatigue and physical activity in older patients with cancer: a six-month follow-up study. Oncol Nurs Forum \n                           36, 194\u2013202, https:\/\/doi.org\/10.1188\/09.ONF.194-202 (2009).","journal-title":"Oncol Nurs Forum"},{"key":"15040_CR61","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11136-007-9215-3","volume":"16","author":"K Meeske","year":"2007","unstructured":"Meeske, K. et al. Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report. Qual Life Res \n                           16, 947\u2013960, https:\/\/doi.org\/10.1007\/s11136-007-9215-3 (2007).","journal-title":"Qual Life Res"},{"key":"15040_CR62","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1002\/cncr.26226","volume":"118","author":"MM Goedendorp","year":"2012","unstructured":"Goedendorp, M. M. et al. Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer \n                           118, 3833\u20133841, https:\/\/doi.org\/10.1002\/cncr.26226 (2012).","journal-title":"Cancer"},{"key":"15040_CR63","doi-asserted-by":"publisher","unstructured":"Christensen, C. O., Cronin-Fenton, D., Froslev, T., Hermann, A. P. & Ewertz, M. Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, doi:https:\/\/doi.org\/10.1007\/s00520-016-3250-y (2016).","DOI":"10.1007\/s00520-016-3250-y"},{"key":"15040_CR64","doi-asserted-by":"publisher","unstructured":"Lee, S. W., Yeo, S. G., Oh, I. H., Yeo, J. H. & Park, D. C. Bone mineral density in women treated for various types of gynecological cancer. Asia Pac J Clin Oncol, doi:https:\/\/doi.org\/10.1111\/ajco.12584 (2016).","DOI":"10.1111\/ajco.12584"},{"key":"15040_CR65","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.radonc.2016.03.002","volume":"118","author":"RL Wei","year":"2016","unstructured":"Wei, R. L. et al. Bone mineral density loss in thoracic and lumbar vertebrae following radiation for abdominal cancers. Radiother Oncol \n                           118, 430\u2013436, https:\/\/doi.org\/10.1016\/j.radonc.2016.03.002 (2016).","journal-title":"Radiother Oncol"},{"key":"15040_CR66","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","volume":"15","author":"A de Gramont","year":"1997","unstructured":"de Gramont, A. et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology \n                           15, 808\u2013815, https:\/\/doi.org\/10.1200\/JCO.1997.15.2.808 (1997).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"15040_CR67","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard, J. Y. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet \n                           355, 1041\u20131047 (2000).","journal-title":"Lancet"},{"key":"15040_CR68","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand, C. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology \n                           22, 229\u2013237, https:\/\/doi.org\/10.1200\/JCO.2004.05.113 (2004).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"15040_CR69","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1634\/theoncologist.2014-0032","volume":"19","author":"MM Kirstein","year":"2014","unstructured":"Kirstein, M. M. et al. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. The oncologist \n                           19, 1156\u20131168, https:\/\/doi.org\/10.1634\/theoncologist.2014-0032 (2014).","journal-title":"The oncologist"},{"key":"15040_CR70","doi-asserted-by":"publisher","first-page":"10316","DOI":"10.3748\/wjg.v20.i30.10316","volume":"20","author":"B Mohelnikova-Duchonova","year":"2014","unstructured":"Mohelnikova-Duchonova, B., Melichar, B. & Soucek, P. FOLFOX\/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. World J Gastroenterol \n                           20, 10316\u201310330, https:\/\/doi.org\/10.3748\/wjg.v20.i30.10316 (2014).","journal-title":"World J Gastroenterol"},{"key":"15040_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.lungcan.2004.07.040","volume":"47","author":"TA Hensing","year":"2005","unstructured":"Hensing, T. A., Schell, M. J., Lee, J. H. & Socinski, M. A. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer \n                           47, 253\u2013259, https:\/\/doi.org\/10.1016\/j.lungcan.2004.07.040 (2005).","journal-title":"Lung Cancer"},{"key":"15040_CR72","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/01.COC.0000071463.72269.2A","volume":"27","author":"B Jeremic","year":"2004","unstructured":"Jeremic, B., Milicic, B., Dagovic, A., Aleksandrovic, J. & Milisavljevic, S. Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients. Am J Clin Oncol \n                           27, 350\u2013360 (2004).","journal-title":"Am J Clin Oncol"},{"key":"15040_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/1535-7163.MCT-06-0591","volume":"6","author":"RS Huang","year":"2007","unstructured":"Huang, R. S., Kistner, E. O., Bleibel, W. K., Shukla, S. J. & Dolan, M. E. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther \n                           6, 31\u201336, https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0591 (2007).","journal-title":"Mol Cancer Ther"},{"key":"15040_CR74","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s00198-016-3672-x","volume":"27","author":"H Fonseca","year":"2016","unstructured":"Fonseca, H. et al. Effects of doxorubicin administration on bone strength and quality in sedentary and physically active Wistar rats. Osteoporos Int \n                           27, 3465\u20133475, https:\/\/doi.org\/10.1007\/s00198-016-3672-x (2016).","journal-title":"Osteoporos Int"},{"issue":"Suppl 3","key":"15040_CR75","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.2215\/CJN.04151206","volume":"3","author":"B Clarke","year":"2008","unstructured":"Clarke, B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol \n                           3(Suppl 3), S131\u2013139, https:\/\/doi.org\/10.2215\/CJN.04151206 (2008).","journal-title":"Clin J Am Soc Nephrol"},{"key":"15040_CR76","doi-asserted-by":"publisher","first-page":"E1440","DOI":"10.1152\/ajpendo.00587.2011","volume":"302","author":"R Raghu Nadhanan","year":"2012","unstructured":"Raghu Nadhanan, R. et al. Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss. American journal of physiology. Endocrinology and metabolism \n                           302, E1440\u20131449, https:\/\/doi.org\/10.1152\/ajpendo.00587.2011 (2012).","journal-title":"American journal of physiology. Endocrinology and metabolism"},{"key":"15040_CR77","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00774-015-0679-x","volume":"34","author":"C Fan","year":"2016","unstructured":"Fan, C. et al. Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. J Bone Miner Metab \n                           34, 277\u2013290, https:\/\/doi.org\/10.1007\/s00774-015-0679-x (2016).","journal-title":"J Bone Miner Metab"},{"key":"15040_CR78","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1152\/japplphysiol.01183.2010","volume":"110","author":"KT Murphy","year":"2011","unstructured":"Murphy, K. T., Cobani, V., Ryall, J. G., Ibebunjo, C. & Lynch, G. S. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. Journal of applied physiology \n                           110, 1065\u20131072, https:\/\/doi.org\/10.1152\/japplphysiol.01183.2010 (2011).","journal-title":"Journal of applied physiology"},{"key":"15040_CR79","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bone.2013.12.002","volume":"60","author":"P Bialek","year":"2014","unstructured":"Bialek, P. et al. A myostatin and activin decoy receptor enhances bone formation in mice. Bone \n                           60, 162\u2013171, https:\/\/doi.org\/10.1016\/j.bone.2013.12.002 (2014).","journal-title":"Bone"},{"key":"15040_CR80","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bone.2015.04.013","volume":"80","author":"J Compston","year":"2015","unstructured":"Compston, J. Emerging therapeutic concepts for muscle and bone preservation\/building. Bone \n                           80, 150\u2013156, https:\/\/doi.org\/10.1016\/j.bone.2015.04.013 (2015).","journal-title":"Bone"},{"key":"15040_CR81","first-page":"E146","volume":"274","author":"JW Chow","year":"1998","unstructured":"Chow, J. W., Fox, S., Jagger, C. J. & Chambers, T. J. Role for parathyroid hormone in mechanical responsiveness of rat bone. The American journal of physiology \n                           274, E146\u2013154 (1998).","journal-title":"The American journal of physiology"},{"key":"15040_CR82","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle, J. L. et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol \n                           30, 312\u2013321, https:\/\/doi.org\/10.1080\/01926230252929882 (2002).","journal-title":"Toxicol Pathol"},{"key":"15040_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","volume":"86","author":"J Jolette","year":"2017","unstructured":"Jolette, J. et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul Toxicol Pharmacol \n                           86, 356\u2013365, https:\/\/doi.org\/10.1016\/j.yrtph.2017.04.001 (2017).","journal-title":"Regul Toxicol Pharmacol"},{"key":"15040_CR84","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative, G. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet \n                           386, 1353\u20131361, doi:https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4 (2015).","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"15040_CR85","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1096\/fj.14-257543","volume":"29","author":"KE O\u2019Connell","year":"2015","unstructured":"O\u2019Connell, K. E. et al. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques. FASEB J \n                           29, 1165\u20131175, https:\/\/doi.org\/10.1096\/fj.14-257543 (2015).","journal-title":"FASEB J"},{"key":"15040_CR86","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1096\/fj.201600271RR","volume":"30","author":"N Bechir","year":"2016","unstructured":"Bechir, N. et al. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo. FASEB J \n                           30, 3551\u20133562, https:\/\/doi.org\/10.1096\/fj.201600271RR (2016).","journal-title":"FASEB J"},{"key":"15040_CR87","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1210\/jc.2014-4318","volume":"100","author":"A Loumaye","year":"2015","unstructured":"Loumaye, A. et al. Role of Activin A and myostatin in human cancer cachexia. The Journal of clinical endocrinology and metabolism \n                           100, 2030\u20132038, https:\/\/doi.org\/10.1210\/jc.2014-4318 (2015).","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"15040_CR88","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1096\/fj.13-245894","volume":"28","author":"JL Chen","year":"2014","unstructured":"Chen, J. L. et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J \n                           28, 1711\u20131723, https:\/\/doi.org\/10.1096\/fj.13-245894 (2014).","journal-title":"FASEB J"},{"key":"15040_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-017-0639-9","volume":"112","author":"TA Zimmers","year":"2017","unstructured":"Zimmers, T. A. et al. Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. Basic research in cardiology \n                           112, 48, https:\/\/doi.org\/10.1007\/s00395-017-0639-9 (2017).","journal-title":"Basic research in cardiology"},{"key":"15040_CR90","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nm.3961","volume":"21","author":"DL Waning","year":"2015","unstructured":"Waning, D. L. et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nature medicine \n                           21, 1262\u20131271, https:\/\/doi.org\/10.1038\/nm.3961 (2015).","journal-title":"Nature medicine"},{"key":"15040_CR91","doi-asserted-by":"publisher","unstructured":"Loumaye, A. et al. Circulating Activin A predicts survival in cancer patients. Journal of cachexia, sarcopenia and muscle, doi:https:\/\/doi.org\/10.1002\/jcsm.12209 (2017).","DOI":"10.1002\/jcsm.12209"},{"key":"15040_CR92","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/jcsm.12145","volume":"8","author":"H Ding","year":"2017","unstructured":"Ding, H. et al. Activin A induces skeletal muscle catabolism via p38beta mitogen-activated protein kinase. Journal of cachexia, sarcopenia and muscle \n                           8, 202\u2013212, https:\/\/doi.org\/10.1002\/jcsm.12145 (2017).","journal-title":"Journal of cachexia, sarcopenia and muscle"},{"key":"15040_CR93","doi-asserted-by":"crossref","first-page":"14233","DOI":"10.1016\/S0021-9258(19)49702-0","volume":"267","author":"Y Ogawa","year":"1992","unstructured":"Ogawa, Y. et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. The Journal of biological chemistry \n                           267, 14233\u201314237 (1992).","journal-title":"The Journal of biological chemistry"},{"key":"15040_CR94","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1006\/bbrc.2000.2075","volume":"268","author":"K Fuller","year":"2000","unstructured":"Fuller, K., Bayley, K. E. & Chambers, T. J. Activin A is an essential cofactor for osteoclast induction. Biochemical and biophysical research communications \n                           268, 2\u20137, https:\/\/doi.org\/10.1006\/bbrc.2000.2075 (2000).","journal-title":"Biochemical and biophysical research communications"},{"key":"15040_CR95","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1210\/endo.143.1.8580","volume":"143","author":"D Gaddy-Kurten","year":"2002","unstructured":"Gaddy-Kurten, D., Coker, J. K., Abe, E., Jilka, R. L. & Manolagas, S. C. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology \n                           143, 74\u201383, https:\/\/doi.org\/10.1210\/endo.143.1.8580 (2002).","journal-title":"Endocrinology"},{"key":"15040_CR96","doi-asserted-by":"publisher","first-page":"13809","DOI":"10.1074\/jbc.M117.782128","volume":"292","author":"BC Goh","year":"2017","unstructured":"Goh, B. C. et al. Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass. The Journal of biological chemistry \n                           292, 13809\u201313822, https:\/\/doi.org\/10.1074\/jbc.M117.782128 (2017).","journal-title":"The Journal of biological chemistry"},{"key":"15040_CR97","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1073\/pnas.0711263105","volume":"105","author":"RS Pearsall","year":"2008","unstructured":"Pearsall, R. S. et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proceedings of the National Academy of Sciences of the United States of America \n                           105, 7082\u20137087, https:\/\/doi.org\/10.1073\/pnas.0711263105 (2008).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"15040_CR98","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.kint.2016.07.039","volume":"91","author":"T Sugatani","year":"2017","unstructured":"Sugatani, T. et al. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney Int \n                           91, 86\u201395, https:\/\/doi.org\/10.1016\/j.kint.2016.07.039 (2017).","journal-title":"Kidney Int"},{"key":"15040_CR99","doi-asserted-by":"publisher","first-page":"e22538","DOI":"10.1371\/journal.pone.0022538","volume":"6","author":"A Bonetto","year":"2011","unstructured":"Bonetto, A. et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PloS one \n                           6, e22538, https:\/\/doi.org\/10.1371\/journal.pone.0022538 (2011).","journal-title":"PloS one"},{"key":"15040_CR100","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/JES.0b013e3181f44f11","volume":"38","author":"JA Carson","year":"2010","unstructured":"Carson, J. A. & Baltgalvis, K. A. Interleukin 6 as a key regulator of muscle mass during cachexia. Exercise and sport sciences reviews \n                           38, 168\u2013176, https:\/\/doi.org\/10.1097\/JES.0b013e3181f44f11 (2010).","journal-title":"Exercise and sport sciences reviews"},{"key":"15040_CR101","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/S0002-9440(10)63608-5","volume":"163","author":"S Kumar","year":"2003","unstructured":"Kumar, S. et al. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol \n                           163, 2531\u20132541 (2003).","journal-title":"Am J Pathol"},{"key":"15040_CR102","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1172\/JCI116897","volume":"92","author":"P Costelli","year":"1993","unstructured":"Costelli, P. et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. The Journal of clinical investigation \n                           92, 2783\u20132789, https:\/\/doi.org\/10.1172\/JCI116897 (1993).","journal-title":"The Journal of clinical investigation"},{"key":"15040_CR103","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1158\/0008-5472.CAN-15-3152","volume":"76","author":"JL Chen","year":"2016","unstructured":"Chen, J. L. et al. Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. Cancer research \n                           76, 5372\u20135382, https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-3152 (2016).","journal-title":"Cancer research"},{"key":"15040_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-2-3","volume":"2","author":"AU Trendelenburg","year":"2012","unstructured":"Trendelenburg, A. U., Meyer, A., Jacobi, C., Feige, J. N. & Glass, D. J. TAK-1\/p38\/nNFkappaB signaling inhibits myoblast differentiation by increasing levels of Activin A. Skelet Muscle \n                           2, 3, https:\/\/doi.org\/10.1186\/2044-5040-2-3 (2012).","journal-title":"Skelet Muscle"},{"key":"15040_CR105","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00198-017-4032-1","volume":"28","author":"AJ Koh","year":"2017","unstructured":"Koh, A. J., Sinder, B. P., Entezami, P., Nilsson, L. & McCauley, L. K. The skeletal impact of the chemotherapeutic agent etoposide. Osteoporos Int \n                           28, 2321\u20132333, https:\/\/doi.org\/10.1007\/s00198-017-4032-1 (2017).","journal-title":"Osteoporos Int"},{"key":"15040_CR106","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jbmr.1969","volume":"28","author":"DJ DiGirolamo","year":"2013","unstructured":"DiGirolamo, D. J., Kiel, D. P. & Esser, K. A. Bone and skeletal muscle: neighbors with close ties. J Bone Miner Res \n                           28, 1509\u20131518, https:\/\/doi.org\/10.1002\/jbmr.1969 (2013).","journal-title":"J Bone Miner Res"},{"key":"15040_CR107","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/1440-1681.12728","volume":"44","author":"YS Chen","year":"2017","unstructured":"Chen, Y. S. et al. GDF8 inhibits bone formation and promotes bone resorption in mice. Clin Exp Pharmacol Physiol \n                           44, 500\u2013508, https:\/\/doi.org\/10.1111\/1440-1681.12728 (2017).","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"15040_CR108","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1172\/JCI0215463","volume":"110","author":"S Yakar","year":"2002","unstructured":"Yakar, S. et al. Circulating levels of IGF-1 directly regulate bone growth and density. The Journal of clinical investigation \n                           110, 771\u2013781, https:\/\/doi.org\/10.1172\/JCI15463 (2002).","journal-title":"The Journal of clinical investigation"},{"key":"15040_CR109","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1074\/jbc.M116.770941","volume":"292","author":"Y Qin","year":"2017","unstructured":"Qin, Y. et al. Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218: A novel mechanism in muscle-bone communication. The Journal of biological chemistry \n                           292, 11021\u201311033, https:\/\/doi.org\/10.1074\/jbc.M116.770941 (2017).","journal-title":"The Journal of biological chemistry"},{"key":"15040_CR110","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0303-7207(01)00496-8","volume":"180","author":"R Sakai","year":"2001","unstructured":"Sakai, R. & Eto, Y. Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol \n                           180, 183\u2013188 (2001).","journal-title":"Mol Cell Endocrinol"},{"key":"15040_CR111","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/jbm.a.31085","volume":"81","author":"B Wildemann","year":"2007","unstructured":"Wildemann, B., Kadow-Romacker, A., Haas, N. P. & Schmidmaier, G. Quantification of various growth factors in different demineralized bone matrix preparations. J Biomed Mater Res A \n                           81, 437\u2013442, https:\/\/doi.org\/10.1002\/jbm.a.31085 (2007).","journal-title":"J Biomed Mater Res A"},{"key":"15040_CR112","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/bonekey.2015.59","volume":"4","author":"DL Waning","year":"2015","unstructured":"Waning, D. L. & Guise, T. A. Cancer-associated muscle weakness: What\u2019s bone got to do with it? Bonekey Rep \n                           4, 691, https:\/\/doi.org\/10.1038\/bonekey.2015.59 (2015).","journal-title":"Bonekey Rep"},{"key":"15040_CR113","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/bonekey.2012.60","volume":"1","author":"MW Hamrick","year":"2012","unstructured":"Hamrick, M. W. The skeletal muscle secretome: an emerging player in muscle-bone crosstalk. Bonekey Rep \n                           1, 60, https:\/\/doi.org\/10.1038\/bonekey.2012.60 (2012).","journal-title":"Bonekey Rep"},{"key":"15040_CR114","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jbmr.2162","volume":"29","author":"E Borsheim","year":"2014","unstructured":"Borsheim, E. et al. Pamidronate attenuates muscle loss after pediatric burn injury. J Bone Miner Res \n                           29, 1369\u20131372, https:\/\/doi.org\/10.1002\/jbmr.2162 (2014).","journal-title":"J Bone Miner Res"},{"key":"15040_CR115","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.molmet.2016.07.002","volume":"5","author":"P Mera","year":"2016","unstructured":"Mera, P., Laue, K., Wei, J., Berger, J. M. & Karsenty, G. Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol Metab \n                           5, 1042\u20131047, https:\/\/doi.org\/10.1016\/j.molmet.2016.07.002 (2016).","journal-title":"Mol Metab"},{"key":"15040_CR116","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2016.02.043","volume":"164","author":"G Karsenty","year":"2016","unstructured":"Karsenty, G. & Olson, E. N. Bone and Muscle Endocrine Functions: Unexpected Paradigms of Inter-organ Communication. Cell \n                           164, 1248\u20131256, https:\/\/doi.org\/10.1016\/j.cell.2016.02.043 (2016).","journal-title":"Cell"},{"key":"15040_CR117","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.bbagen.2012.11.009","volume":"1830","author":"CC Fontes-Oliveira","year":"2013","unstructured":"Fontes-Oliveira, C. C. et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta \n                           1830, 2770\u20132778, https:\/\/doi.org\/10.1016\/j.bbagen.2012.11.009 (2013).","journal-title":"Biochim Biophys Acta"},{"key":"15040_CR118","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1093\/hmg\/ddv288","volume":"24","author":"YS Lee","year":"2015","unstructured":"Lee, Y. S. et al. Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. Hum Mol Genet \n                           24, 5711\u20135719, https:\/\/doi.org\/10.1093\/hmg\/ddv288 (2015).","journal-title":"Hum Mol Genet"},{"key":"15040_CR119","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/bonekey.2015.101","volume":"4","author":"A Bonetto","year":"2015","unstructured":"Bonetto, A., Andersson, D. C. & Waning, D. L. Assessment of muscle mass and strength in mice. Bonekey Rep \n                           4, 732, https:\/\/doi.org\/10.1038\/bonekey.2015.101 (2015).","journal-title":"Bonekey Rep"},{"key":"15040_CR120","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods \n                           9, 671\u2013675 (2012).","journal-title":"Nat Methods"},{"key":"15040_CR121","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/jbmr.141","volume":"25","author":"ML Bouxsein","year":"2010","unstructured":"Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. Journal of Bone and Mineral Research \n                           25, 1468\u20131486 (2010).","journal-title":"Journal of Bone and Mineral Research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15040-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15040-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15040-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:48:15Z","timestamp":1671799695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15040-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["15040"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-15040-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]},"assertion":[{"value":"30 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14470"}}